Michael Chambers
CEO
Description:
Michael Chambers is the Co-Founder at Agathos Biologics.Michael’s vision and leadership of Aldevron has resulted in several milestones including the 2004 acquisition of Genovac Antibody Technology of Freiburg, Germany; the 2009 expansion of protein production in Madison, Wisconsin; private equity transactions by TA Associates in 2017 and EQT in 2020; and the purchase of Aldevron by Danaher for $9.6 billion in 2021. Michael is committed to ethical pharmaceutical development and his leadership will enable Agathos to create new paradigms in biotechnology to achieve these goals. Michael received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from North Dakota State University.
Summary:
Michael Chambers is the Co-Founder at Agathos Biologics.Michael’s vision and leadership of Aldevron has resulted in several milestones inclu...
Number of Registered Investments:3
Contact Details:
- Address: Fargo, North Dakota, United States
- No email is provided
Location:Fargo, North Dakota, United States
Email is Not Provided
Phone Number:Fargo, North Dakota, United States
Updated August 2023. This content was crafted by an associate of Najafi Capital (“Najafi”) and is presented strictly for informational objectives. The details on this page neither advocate for nor dissuade the subscription, acquisition, or sale of any security or offering. The material Najafi evaluates for project owner screening and due diligence stems directly from the project owner presenting the investment opportunity. While Najafi perceives the information to have been sourced from trustworthy channels, there is no absolute assurance, warranty, or representation concerning its authenticity. Najafi renounces any liability regarding content provided by the project owner, inclusive of the data utilized to fulfill elements outlined on this page. Najafi is not accountable for the precision, legality, or the affirmation of subsequent details shared by the project owner.
Prospective investors are urged to perform their individual due diligence and authenticate the provided data. Investing inherently encompasses risks, inclusive of the potential loss of capital invested. All investors are recommended to ponder over these aspects in tandem with a chosen professional consultant to ascertain the suitability of an investment.